Bursa Securities waives need for Group to submit regularisation plan
PETALING JAYA, Malaysia, June 13, 2022 – (ACN Newswire) – Malaysian Genomics Resource Centre Berhad MGRC 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce that it is uplifted from being classified as an affected listed corporation effective 13 June 2022.
|Azri Azerai, Executive Director of Malaysian Genomics|
|Sasha Nordin, CEO and Dato’ Alvin Nesakumar, Executive Director of Malaysian Genomics [L-R]|
This followed the decision by Bursa Securities Malaysia Berhad to grant the Group a waiver in submitting a regularisation plan after being classified as an affected listed corporation pursuant to Rule 8.03A of the Listing Requirements. Bursa Securities had made the classification according to Rule 8.03A on 24 December 2019 and Malaysian Genomics had submitted an application seeking approval to exempt the Group from submitting a proposed regularisation plan on 24 March 2022. The waiver was granted on 10 June 2022.
Encik Azri Azerai, Executive Director of Malaysian Genomics, said, “I am extremely thankful to the team for working diligently to get Malaysian Genomics out of the affected issuer classification status and welcome this news from the regulator. Our diversification into biopharmaceutical services, in particular the distribution of immunotherapy and cell therapies, has supported the financial performance of the Group. I believe that we can grow together, as a team.”
In a recent announcement on its 3Q 2022 performance, Malaysian Genomics reported a profit before tax (PBT) of RM1.96 million compared with PBT of RM0.2 million in 3Q 2021. Earnings per share (EPS) stood at 1.60 sen for 3Q 2022 compared with EPS of 0.19 sen in the corresponding quarter of the previous financial year.
Mr. Sasha Nordin, Chief Executive Officer of Malaysian Genomics said, “We will continue to seek opportunities through collaborations and partnerships targeting new consumer and market segments,…